Cardiovascular Outcomes of GLP‐1–Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta‐Analyses of Randomized Controlled Trials
Obesity Reviews · 22.07.2026
DOI: 10.1111/obr.70198 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity Reviews, online erschienen am 22.07.2026. Verfasst von Muhammed Rashid und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Cardiovascular (CV) outcomes of Glucagon‐like peptide‐1 (GLP‐1)–based medicines among people with overweight and obese (OW/OB) population have been investigated by meta‐analyses of randomized controlled trials (RCTs), but an overall summary is lacking.
Methods
PubMed, EMBASE, Epistemonikos, and Cochrane databases were searched till May 2024 for meta‐analyses of RCTs that assessed CV outcomes of GLP‐1–based medicines among people with OW/OB. GRADE approach was used to assess strength of associations.
Results
Nine studies with 58 unique meta‐analyses were included. Fifteen (25.9%) associations were statistically significant. Five high certainty evidence demonstrated beneficial effects of GLP‐1 RAs on any CV events ( N = 1), major adverse cardiac events (MACE) ( N = 2), and myocardial infarction (MI) ( N = 2), whereas two associations on revascularization ( N = 1) and CV events ( N = 1) were supported by moderate certainty. Four associations demonstrated inverse effects of tirzepatide on MACE ( N = 1; moderate) and hypertension ( N = 3; low). Remaining four demonstrated higher risk of arrhythmia with GLP‐1 RAs ( N = 1; moderate) and increased heart rate with tirzepatide ( N = 3; low to moderate). Although the inverse association between GLP‐1 RAs and MACE and MI was significant and supported by high certainty evidence in both main and sensitivity analyses, these associations were no longer statistically significant among patients without CV disease (CVD) at baseline.
Conclusion
Findings suggest that GLP‐1 RAs are associated with reduced risk of MACE, and MI among people with OW/OB, but they were driven by studies with established CVD at baseline.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
- Independent Researcher, Kuala Lumpur, Malaysia.
- Department of Pharmacy Practice, School of Pharmacy, IMU University, Kuala Lumpur, Malaysia.
- Advancing Collaboration, Translation, and Innovation for Value in Evidence Synthesis (ACTIVES) Hub of Talent, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.
- The Research Unit of Evidence Synthesis (TRUES), Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.
- Trillium Health Partners and St. Michael's Hospital and Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Teerapon Dhippayom, Nathorn Chaiyakunapruk
Zitieren
APA
Rashid, M., Lee, E. L., Veettil, S. K., Dhippayom, T., Cheng, A. Y. Y., Simonetti, J., & Chaiyakunapruk, N. (2026). Cardiovascular Outcomes of GLP‐1–Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta‐Analyses of Randomized Controlled Trials. Obesity Reviews. https://doi.org/10.1111/obr.70198
Vancouver
Rashid M, Lee EL, Veettil SK, Dhippayom T, Cheng AYY, Simonetti J, et al. Cardiovascular Outcomes of GLP‐1–Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta‐Analyses of Randomized Controlled Trials. Obesity Reviews. 2026. doi:10.1111/obr.70198
BibTeX
@article{Rashid2026,
author = {Rashid, Muhammed and Lee, E Lyn and Veettil, Sajesh K and Dhippayom, Teerapon and Cheng, Alice Y Y and Simonetti, Juliana and Chaiyakunapruk, Nathorn},
title = {Cardiovascular Outcomes of GLP‐1–Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta‐Analyses of Randomized Controlled Trials},
journal = {Obesity Reviews},
year = {2026},
doi = {10.1111/obr.70198}
}
EUVIMED